|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
J05AF06
|
|
gptkbp:brand
|
gptkb:Ziagen
|
|
gptkbp:CASNumber
|
188062-50-2
|
|
gptkbp:chemicalClass
|
carbocyclic nucleoside analogue
|
|
gptkbp:combinationTherapy
|
gptkb:Triumeq
gptkb:Epzicom
gptkb:Trizivir
|
|
gptkbp:contraindication
|
HLA-B*5701 positive patients
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:drugBank_ID
|
DB01048
|
|
gptkbp:eliminationHalfLife
|
1.5 hours
|
|
gptkbp:FDAApproved
|
1998
|
|
gptkbp:hasMolecularFormula
|
C14H18N6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abacavir sulfate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
protease inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B3 (Australia)
|
|
gptkbp:proteinBinding
|
49%
|
|
gptkbp:PubChem_CID
|
441300
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
rash
hypersensitivity reaction
|
|
gptkbp:synonym
|
gptkb:ABC
(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-methanol sulfate
|
|
gptkbp:UNII
|
P0A9O6QL5Q
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:abacavir
|
|
gptkbp:bfsLayer
|
6
|